Stance Capital’s Biogen BIIB Stock Holding History

Stance Capital’s Portfolio BIIB Stock Details BIIB Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	–	Sell	-81	Closed	-$14.8K	–	349
2026 Q1	$14.8K	Buy	+81	New	+$14.9K	0.01%	220
2025 Q1	–	Sell	-3	Closed	-$459	–	76
2024 Q4	$459	Buy	+3	New	+$506	﹤0.01%	245

Other funds holding BIIB

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Primecap Management Pasadena, California $169B AUM 114.72% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

Norges Bank Oslo, Norway $1T AUM

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Stance Capital's BIIB Position: Q2 2026 in Review

Stance Capital sold out of Biogen (BIIB) in Q2 2026, closing a stake of 81 shares — an estimated $14.8K sold.

Stance Capital first reported a position in BIIB in Q4 2024 and held it in 2 quarters. The position peaked at $14.8K in Q1 2026. 1,043 funds tracked by Wall St. Rank hold BIIB as of Q2 2026.

Stance Capital reported no remaining Biogen position as of Q2 2026 after selling out during the quarter.
Stance Capital sold 81 Biogen shares in Q2 2026, an estimated $14.8K.
Stance Capital first reported a position in Biogen in Q4 2024 and held it in 2 quarters.
Stance Capital's Biogen position peaked at $14.8K in Q1 2026.
1,043 funds tracked by Wall St. Rank held Biogen as of Q2 2026.

Based on Stance Capital's 13F filing for Q2 2026, filed 14 Aug 2026.